Peripheral Interventions

The Eluvia™ Drug-Eluting Vascular Stent System is specifically developed for the treatment of peripheral artery disease (PAD). The Eluvia stent utilizes a drug-polymer combination to offer sustained release of the drug paclitaxel for a one-year timeframe, designed to prevent tissue regrowth that might otherwise block the stented artery. The Eluvia stent was approved by the FDA based on findings from the IMPERIAL trial, in which the Eluvia stent demonstrated superior results in the first superficial femoral artery head-to-head drug-eluting stent trial.

The Ranger™ Drug-Coated Balloon was developed for the treatment of patients with peripheral artery disease (PAD) in the superficial femoral artery (SFA) and proximal popliteal artery (PPA). Approximately 200 million people around the world are affected by PAD, a common circulatory problem in which plaque builds up and narrows arteries, consequently reducing blood flow to limbs. The Ranger DCB was designed with a low therapeutic drug dose and proprietary coating which efficiently transfers the drug into the tissue, resulting in high primary patency rates and low systemic drug exposure for patients. The low-profile platform of the balloon also assists clinicians in performing streamlined procedures and navigating through challenging anatomy in order to deliver consistent therapy.

Embold Fibered is a fully retractable, .018” coil built to maximize procedural flexibility and reliability. This embolic coil is used for arterial and venous embolizations in the peripheral vasculature of adults. Embold takes coiling simplicity to a new level, offering multi-catheter compatibility to lessen procedure time and complexity; a nitinol delivery system that’s resistant to kinking and premature detachment; handle-free detachment to reduce procedure steps and cost; and occlusion power for more certainty.

TheraSphere™ is a radioembolization treatment for patients diagnosed with primary liver cancer and metastatic liver cancer.* It is a targeted therapy that consists of millions of glass microspheres containing radioactive yttrium-90. TheraSphere™ is delivered into the hepatic artery to selectively target and destroy tumor cells while minimizing distribution and impact to normal tissue. The radioactive microspheres continue to deliver radiation to the tumor over the course of several weeks after treatment.

The EKOS Acoustic Pulse Thrombolysis™ System, the first endovascular device cleared by the FDA for the treatment of pulmonary embolism (PE), which is designed to leverage targeted ultrasonic waves in combination with clot-dissolving drugs in the treatment of peripheral thrombus.